Alpha Cognition Inc.

Alpha Cognition Inc. is a biopharmaceutical company dedicated to developing and commercializing treatments for neurodegenerative diseases, primarily focusing on Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The company's mission is to provide therapeutic options for conditions that currently have limited or no approved treatments. Alpha Cognition is headquartered in Vancouver, Canada, with an additional corporate office in Grapevine, Texas.

The company's flagship commercial product is ZUNVEYL® (benzgalantamine), an oral tablet formulation approved for the treatment of mild to moderate Alzheimer's disease. ZUNVEYL is characterized as a new generation acetylcholinesterase inhibitor designed to minimize gastrointestinal side effects while also targeting neuronal nicotinic receptors. Beyond ZUNVEYL, Alpha Cognition maintains a pipeline of preclinical development programs, including ZUNVEYL in combination with memantine for moderate-to-severe Alzheimer's, a sublingual formulation of ALPHA-1062, and an intranasal formulation of ALPHA-1062 for cognitive impairment with mTBI. The company is also advancing ALPHA-0602, a gene therapy program for Amyotrophic Lateral Sclerosis (ALS).

Michael McFadden serves as the Chief Executive Officer and a Director of Alpha Cognition Inc. In 2025, the company reported total revenue of $10.2 million, primarily driven by ZUNVEYL net product revenue. Alpha Cognition is actively engaged in expanding the commercial reach of ZUNVEYL, including securing national Pharmacy Benefit Manager (PBM) contracts and initiating real-world effectiveness studies. Recent corporate developments include the appointment of Bethany Sensenig to the Board of Directors in April 2026, with an expectation for her to chair the Audit Committee. The company has stated a target of achieving operating profitability by 2027.